WO2023112001 - AN IMPROVED ASSAY METHOD FOR DETERMINING THE POTENCY OF RECOMBINANT PROTEIN
National phase entry:
Publication Number
WO/2023/112001
Publication Date
22.06.2023
International Application No.
PCT/IB2022/062427
International Filing Date
17.12.2022
Title **
[English]
AN IMPROVED ASSAY METHOD FOR DETERMINING THE POTENCY OF RECOMBINANT PROTEIN
[French]
PROCÉDÉ DE DOSAGE AMÉLIORÉ POUR DÉTERMINER LA PUISSANCE D'UNE PROTÉINE RECOMBINANTE
Applicants **
KASHIV BIOSCIENCES, LLC
Inventors
SHARMA, Shalini
ANIDIL KIZHAKINAGATH, Praveen Kumar
JASH, Kavya Siddhartha
Priority Data
202121058990
17.12.2021
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
* |
| * | |
| Recordal of a Change of the Applicant's Name/Address | * |
| Type of Assignment | * |
| Applicant's Legal Status | * |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under | * |
| Patent Delivery | * |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2305 | |
| EPO | Filing, Examination, Granting | 13997 | |
| Japan | Filing, Examination, Granting | 2440 | |
| South Korea | Filing, Examination, Granting | 2688 | |
| USA | Filing, Examination, Granting | 4510 |
Total:
25,940
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention provides an improved assay method for determining the potency of recombinant proteins by culturing the immune cells such as antigen presenting cell and/or T cell in culture media comprising FBS less than 10%. Furthermore, the invention provides a method to eliminate or reduce the false estimation of potency of target recombinant protein. The assay method determines the potency of recombinant protein by evaluating the expression of inflammatory protein. More specifically the present invention describes the IL-2 inhibition assays for determination of potency of CTLA4 IgG1.[French]
La présente invention concerne un procédé de dosage amélioré pour déterminer la puissance de protéines recombinantes par culture des cellules immunitaires telles qu'une cellule présentatrice d'antigène et/ou une cellule T dans des milieux de culture comprenant un SVF inférieur à 10 %. En outre, l'invention concerne un procédé pour éliminer ou réduire la fausse estimation de puissance de protéine recombinante cible. Le procédé de dosage détermine la puissance de la protéine recombinante par évaluation de l'expression de la protéine inflammatoire. Plus spécifiquement, la présente invention décrit les dosages d'inhibition d'IL-2 pour déterminer la puissance de CTLA4 IgG1.